Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study

Arianna Di Stadio, Evanthia Bernitsas, Domenico Antonio Restivo, Enrico Alfonsi, Rosario Marchese-Ragona

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: This study aims to evaluate the effect of botulin toxin A in patients with multiple sclerosis (MS) affected by spasmodic dysphonia (SD) and to show the safety and effectiveness of this treatment in long-term observation.

MATERIALS AND METHODS: This is a pilot study on three relapsing-remitting MS patients with SD and their response to botulin toxin A.

RESULTS: None of the patients reported dysphagia or other adverse events. Significant improvement was observed in terms of both voice quality and laryngostroboscopy results. The treatment effect was durable for 6-8 months.

CONCLUSIONS: Botulin toxin A is a safe treatment that can be successfully used to treat SD in patients with MS. Larger studies are necessary to confirm our results.

Original languageEnglish
JournalJournal of Voice
DOIs
Publication statusE-pub ahead of print - Apr 9 2018

Fingerprint Dive into the research topics of 'Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study'. Together they form a unique fingerprint.

Cite this